Abstract

The use of cost-effective vaccines capable of inducing robust CD8+ T cell immunity will contribute significantly towards the elimination of persistent viral infections and cancers worldwide. We have previously reported that a cytolytic DNA vaccine encoding an immunogen and a truncated mouse perforin (PRF) protein significantly augments anti-viral T cell (including CD8+ T cell) immunity. Thus, the current study investigated whether this vaccine enhances activation of dendritic cells (DCs) resulting in greater priming of CD8+ T cell immunity. In vitro data showed that transfection of HEK293T cells with the cytolytic DNA resulted in the release of lactate dehydrogenase, indicative of necrotic/lytic cell death. In vitro exposure of this lytic cell debris to purified DCs from naïve C57BL/6 mice resulted in maturation of DCs as determined by up-regulation of CD80/CD86. Using activation/proliferation of adoptively transferred OT-I CD8+ T cells to measure antigen presentation by DCs in vivo, it was determined that cytolytic DNA immunisation resulted in a time-dependent increase in the proliferation of OT-I CD8+ T cells compared to canonical DNA immunisation. Overall, the data suggest that the cytolytic DNA vaccine increases the activity of DCs which has important implications for the design of DNA vaccines to improve their translational prospects.

Details

Title
Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner
Author
Wijesundara, Danushka K 1 ; Yu, Wenbo 2 ; Quah, Ben J C 3 ; Eldi, Preethi 4 ; Hayball, John D 5 ; Diener, Kerrilyn R 5   VIAFID ORCID Logo  ; Voskoboinik, Ilia 6 ; Gowans, Eric J 1 ; Grubor-Bauk, Branka 1 

 Virology Laboratory, The Basil Hetzel Institute for Translational Health Research, The University of Adelaide, Adelaide, South Australia, Australia 
 Translational Oncology Laboratory, Centre for Cancer Biology, Adelaide, South Australia, Australia 
 Cancer & Vascular Biology Laboratory, The John Curtin School of Medical Research, Canberra, The Australian Capital Territory, Australia 
 Experimental Therapeutics Laboratory, Sansom Institute for Health Research, Adelaide, South Australia, Australia; School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia 
 Experimental Therapeutics Laboratory, Sansom Institute for Health Research, Adelaide, South Australia, Australia; School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia; Robinson Research Institute and Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia 
 Killer Cell Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia 
Pages
1-8
Publication year
2017
Publication date
Aug 2017
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1957244080
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.